Lantheus Holdings, Inc. (LNTH)
LNTHNASDAQ-GMBiotechnology: In Vitro & In Vivo Diagnostic Substances
$101.62
+0.6100 (+0.60%) today
At the close, Nov 10, 4:00 PM ET. After hours $102.00 +0.37%
- Market cap
- $6.65bn
- P/E
- 18.8
- EPS, last 4 quarters
- $5.42
- Dividend yield
- –
- Day range
- $101.00 to $101.68
- 52-week range
- $50.16 to $111.86
- Average volume
- 995.5k
- Previous close
- $101.01
Analysts
4 coveringHold0 buy, 4 hold, 0 sell
Targets a year out average $107.20, +5.5% from here
Earnings
next estimate $1.08Next report
Dec 2025
+55.3%
Mar 2026
+18.6%
Jun 2026
+18.9%
Sep 2026
+41.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $406.79m | $377.33m | $388.18m | $389.91m |
| Gross profit | $240.88m | $230.92m | $241.85m | $243.41m |
| Operating income | $77.18m | $81.33m | $100.22m | $32.21m |
| Net income | $54.09m | $118.42m | $75.03m | $22.37m |
Last four quarters: revenue $1.56bn, margin 17.3%, free cash flow $393.09m
News
8 latest- Lantheus Holdings, Inc. Reports Third Quarter 2026 Revenue of $389.9 millionFintel · 5 days ago
- Lantheus Holdings, Inc. Receives FTC Second Request Regarding MergerFintel · Oct 22, 2026
- GE HealthCare Wins Approval for MINItrace Magni Cyclotron in EuropeZacks · Oct 20, 2026
- FDA Drug Approvals In September 2026 RTTNews · Oct 16, 2026
- AVUV, MATX, GATX, LNTH: Large Outflows Detected at ETFBNK Invest · Oct 12, 2026
- Noteworthy ETF Inflows: AVUV, MATX, GATX, LNTHBNK Invest · Oct 2, 2026
- Notable ETF Outflow Detected - AVUV, MATX, GATX, LNTHBNK Invest · Sep 24, 2026
- FDA Approves Lantheus' Bravnetsa As Equivalent To Lutathera For Neuroendocrine Tumors RTTNews · Sep 22, 2026
The company
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- lantheus.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.